FERMENTA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fermenta Biotech reported a strong turnaround in Q1FY26 (quarter ended June 30, 2025). Consolidated revenue rose 79% year-on-year to INR 145 crore, and EBITDA jumped 922% YoY to INR 37 crore. Profit after tax swung to INR 21.6 crore from a INR 5.9 crore loss a year ago, translating to an EPS of INR 7.49. Volume growth was led by human nutrition (+83% YoY) and animal nutrition (+45% YoY), while the German subsidiary's revenue surged 588% to INR 15.7 crore. The company also incorporated a new environmental solutions subsidiary, signed an MoU with NIFTEM-T for a Centre of Excellence in food fortification, and received EDQM certification for European market expansion.
This is a strong earnings beat with a clear turnaround story — from a loss-making quarter last year to INR 21.6 crore in profit, supported by broad-based volume growth across nutrition segments. The new subsidiary, partnerships, and European certification suggest future revenue catalysts, though the 35% QoQ decline in PAT and 9% QoQ drop in EBITDA indicate some moderation versus the previous quarter.